ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Ceftazidime and avibactam: Drug information

Ceftazidime and avibactam: Drug information
(For additional information see "Ceftazidime and avibactam: Patient drug information" and see "Ceftazidime and avibactam: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Avycaz
Pharmacologic Category
  • Cephalosporin Combination
Dosing: Adult

Note: Dosage recommendations are expressed as total grams of the ceftazidime/avibactam combination. Not recommended for routine empiric use. Reserve use for patients with or at risk for certain extensively drug-resistant gram-negative pathogens (nonsusceptible to ≥1 agent in all but 2 or fewer antimicrobial classes) (eg, carbapenem-resistant Enterobacterales, P. aeruginosa with difficult-to-treat resistance [DTR-P. aeruginosa]) (Ref). Some experts extend infusion time (ie, over 3 hours instead of standard 2 hours) for infections caused by carbapenem-resistant Enterobacterales, DTR-P. aeruginosa, and S. maltophilia (Ref).

Intra-abdominal infection

Intra-abdominal infection (alternative agent):

IV: 2.5 g every 8 hours in combination with metronidazole (Ref). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (Ref).

Pneumonia, hospital-acquired or ventilator-associated

Pneumonia, hospital-acquired or ventilator-associated (alternative agent): IV: 2.5 g every 8 hours (Ref). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (Ref).

Stenotrophomonas maltophilia infection, multidrug-resistant

Stenotrophomonas maltophilia infection, multidrug-resistant (off-label use): IV: 2.5 g every 8 hours; use in combination with aztreonam (administered at the same time, if possible) (Ref).

Urinary tract infection, complicated

Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):

IV: 2.5 g every 8 hours (Ref). Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Dosage recommendations are expressed as total grams of the ceftazidime/avibactam combination.

Altered kidney function (Ref):

Note: Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.

IV:

CrCl >50 to <130 mL/minute: No dosage adjustment necessary.

CrCl >30 to 50 mL/minute: 1.25 g every 8 hours.

CrCl >15 to 30 mL/minute: 0.94 g every 12 hours.

CrCl >5 to 15 mL/minute: 0.94 g every 24 hours.

CrCl ≤5 mL/minute: 0.94 g every 48 hours.

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2):

Note: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

IV: 2.5 g every 8 hours (Ref).

Hemodialysis, intermittent (thrice weekly): Dialyzable (~57% ceftazidime; 55% avibactam (Ref)): 0.94 g every 24 hours; in patients with minimal residual kidney function and less severe infections, may consider administering 0.94 g every 48 hours. When scheduled dose falls on a dialysis day, administer after hemodialysis (Ref).

Peritoneal dialysis:

IV: 0.94 g every 24 hours; in patients with minimal residual kidney function and less severe infections, may consider administering 0.94 g every 48 hours (Ref).

CRRT:

Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.

IV: 1.25 g every 8 hours (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration):

Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.

IV:

On PIRRT days: 1.25 g every 12 hours (administer 1 of the twice-daily doses after PIRRT session). Patients receiving prolonged daily treatments (eg, 12 hours a day) may require dosing every 8 hours (Ref).

On non-PIRRT days: Dose as for CrCl ≤15 mL/minute (Ref).

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Ceftazidime and avibactam: Pediatric drug information")

Note: Avycaz (ceftazidime and avibactam) is a combination product; each 2.5 g vial contains 2 g ceftazidime and 0.5 g avibactam sodium in a 4:1 ratio. Dosage recommendations are based on the ceftazidime component. Dosing presented is based on traditional infusion method (IV infusion over 2 hours).

Intra-abdominal infection, complicated

Intra-abdominal infection, complicated (cIAI): Note: Use in combination with metronidazole. The manufacturer recommends treating for 5 to 14 days depending upon severity and clinical response; a 5-day duration following source control is recommended for pediatric patients in guidelines (Ref).

Infants ≥3 to <6 months: IV: 40 mg ceftazidime/kg/dose every 8 hours.

Infants ≥6 months, Children, and Adolescents <18 years: IV: 50 mg ceftazidime/kg/dose every 8 hours; maximum dose: 2,000 mg ceftazidime/dose.

Adolescents ≥18 years: 2,000 mg ceftazidime every 8 hours.

Urinary tract infection, complicated

Urinary tract infection, complicated (cUTI) (including pyelonephritis): Note: The manufacturer recommends treating for 7 to 14 days depending upon severity and clinical response; durations as short as 6 to 10 days may be appropriate in children ≥2 years and adolescents (Ref).

Infant ≥3 to <6 months: IV: 40 mg ceftazidime/kg/dose every 8 hours.

Infants ≥6 months, Children, and Adolescents <18 years: IV: 50 mg ceftazidime/kg/dose every 8 hours; maximum dose: 2,000 mg ceftazidime/dose.

Adolescents ≥18 years: 2,000 mg ceftazidime every 8 hours.

Pneumonia, hospital-acquired and ventilator-associated

Pneumonia, hospital-acquired and ventilator-associated (HAP/VAP): Note: The manufacturer recommends treating for 7 to 14 days; 7-day treatment durations are recommended in adults (Ref).

Infant ≥3 to <6 months: IV: 40 mg ceftazidime/kg/dose every 8 hours.

Infants ≥6 months, Children, and Adolescents <18 years: IV: 50 mg ceftazidime/kg/dose every 8 hours; maximum dose: 2,000 mg ceftazidime/dose.

Adolescents ≥18 years: IV: 2,000 mg ceftazidime every 8 hours.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Note: Dosage recommendations are based on the ceftazidime component.

Infants ≥3 months and Children <2 years: There are no dosage adjustments provided in the manufacturer's labeling; insufficient data to provide any recommendations for use in patients with eGFR <50 mL/minute/1.73 m2; use with caution.

Children ≥2 years and Adolescents <18 years: IV: Note: Use bedside Schwartz formula to estimate renal function for the purpose of drug dosing.

eGFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.

eGFR 31 to 50 mL/minute/1.73 m2: 25 mg ceftazidime/kg/dose every 8 hours; maximum dose: 1,000 mg ceftazidime/dose.

eGFR 16 to 30 mL/minute/1.73 m2: 19 mg ceftazidime/kg/dose every 12 hours; maximum dose: 750 mg ceftazidime/dose.

eGFR 6 to 15 mL/minute/1.73 m2: 19 mg ceftazidime/kg/dose every 24 hours; maximum dose: 750 mg ceftazidime/dose.

eGFR ≤5 mL/minute/1.73 m2: 19 mg ceftazidime/kg/dose every 48 hours; maximum dose: 750 mg ceftazidime/dose.

End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days; base dose upon patient's estimated renal function (eg, eGFR 6 to 15 mL/minute/1.73 m2 or eGFR ≤5 mL/minute/1.73 m2). Approximately 55% (based on a ceftazidime 1,000 mg dose and avibactam 100 mg dose) is removed following a 4-hour dialysis session.

Adolescents ≥18 years: IV: Note: Use Cockcroft-Gault formula to estimate renal function for the purpose of drug dosing.

CrCl >50 mL/minute: No dosage adjustment necessary.

CrCl 31 to 50 mL/minute: 1,000 mg ceftazidime every 8 hours.

CrCl 16 to 30 mL/minute: 750 mg ceftazidime every 12 hours.

CrCl 6 to 15 mL/minute: 750 mg ceftazidime every 24 hours.

CrCl ≤5 mL/minute: 750 mg ceftazidime every 48 hours.

End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days; base dose upon patient's estimated renal function (eg, CrCl 6 to 15 mL/minute or CrCl ≤5 mL/minute). Approximately 55% (based on a ceftazidime 1,000 mg dose and avibactam 100 mg dose) is removed following a 4-hour dialysis session.

Dosing: Hepatic Impairment: Pediatric

Infants ≥3 months, Children, and Adolescents: No dosage adjustment necessary.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see ceftazidime monograph.

>10%: Hematologic & oncologic: Positive direct coombs test (3% to 21%)

1% to 10%:

Dermatologic: Injection site phlebitis (children and adolescents: >3%; adults: <1%), skin rash (children and adolescents: >3%; adults: <1%), pruritus (2%)

Gastrointestinal: Vomiting (>3%), diarrhea (≥3%), nausea (3%), constipation (2%), upper abdominal pain (1%)

<1%, postmarketing, and/or case reports: Acute renal failure, anxiety, candidiasis, Clostridioides difficile-associated diarrhea, dysgeusia, hypokalemia, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, leukopenia, maculopapular rash, nephrolithiasis, renal insufficiency, thrombocythemia, thrombocytopenia, urticaria

Contraindications

Known serious hypersensitivity to ceftazidime, avibactam, other cephalosporins, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam drugs. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or carbapenem hypersensitivity. Use caution if given to a patient with a penicillin or other beta-lactam allergy; cross sensitivity has been established. If an allergic reaction occurs, discontinue and institute appropriate management.

• Neurotoxicity: Severe neurological reactions have been reported with ceftazidime, including asterixis, coma, encephalopathy, myoclonus, neuromuscular excitability, seizures, and nonconvulsive status epilepticus. Risk may be increased in the presence of renal impairment; ensure dose adjusted for renal function. Discontinue therapy if patient develops neurotoxicity.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Renal impairment: In a complicated intra-abdominal infection clinical trial, adult patients with a CrCl of 30 to 50 mL/minute had lower clinical cure rates than those with CrCl >50 mL/minute; however, these patients received a daily dose that was 33% lower than what is currently recommended for patients with this degree of renal impairment. Decreased clinical response was not seen in patients with a baseline CrCl of 30 to 50 mL/minute in complicated UTI clinical trials. Monitor renal function at baseline and at least daily in adult and pediatric patients with changing renal function. Adjust the dose accordingly.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous [preservative free]:

Avycaz: Ceftazidime 2 g and avibactam 0.5 g (1 ea)

Generic Equivalent Available: US

No

Pricing: US

Solution (reconstituted) (Avycaz Intravenous)

2.5 (2-0.5) g (per each): $452.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

IV: Administer by intermittent infusion over 2 hours. Some experts extend infusion time to 3 hours for infections caused by carbapenem-resistant Enterobacterales, P. aeruginosa with difficult-to-treat resistance, and S. maltophilia (IDSA [Tamma 2022a]; IDSA [Tamma 2022b]).

Administration: Pediatric

IV: Administer by intermittent IV infusion over 2 hours.

Use: Labeled Indications

Intra-abdominal infections: Treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients ≥3 months of age, in combination with metronidazole, caused by Citrobacter freundii complex, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.

Pneumonia, hospital-acquired and ventilator-associated: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated (HAP/VAP) bacterial pneumonia in adult and pediatric patients ≥3 months of age caused by ceftazidime/avibactam-susceptible K. pneumoniae, E. cloacae, E. coli, Serratia marcescens, P. mirabilis, P. aeruginosa, and Haemophilus influenzae.

Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms): Treatment of complicated urinary tract infections (including pyelonephritis) in adult and pediatric patients ≥3 months of age, caused by C. freundii complex, E. cloacae, E. coli, K. pneumoniae, P. mirabilis, and P. aeruginosa.

Use: Off-Label: Adult

Stenotrophomonas maltophilia infection

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Chloramphenicol (Systemic): May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Risk D: Consider therapy modification

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Furosemide: May enhance the nephrotoxic effect of Cephalosporins. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Avibactam. Risk X: Avoid combination

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Adverse events have not been observed in animal reproduction studies conducted with ceftazidime; adverse events have been observed in some animal reproduction studies conducted with avibactam.

Breastfeeding Considerations

Ceftazidime is excreted in breast milk. It is not known if avibactam is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.

Monitoring Parameters

Monitor for signs of anaphylaxis during first dose. Monitor renal function at baseline in all patients, and at least daily in patients with changing renal function.

Mechanism of Action

Ceftazidime inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Avibactam inactivates some beta-lactamases and protects ceftazidime from degradation.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vd:

Single dose: Adults: Mean: Ceftazidime: 18.1 L; Avibactam: 23.2 L

Multiple dose: Adults: Mean: Ceftazidime: 17 L; Avibactam: 22.2 L

Protein binding: Ceftazidime: <10%; Avibactam: 5.7% to 8.2%

Metabolism: Ceftazidime: ~80% to 90% of dose eliminated as unchanged drug; Avibactam: Not metabolized

Half-life elimination:

Single dose:

Ceftazidime:

Children ≥6 years to <12 years: Median: 1.6 hours (0.9 to 1.8 hours) (Bradley 2016)

Children ≥12 years and Adolescents: Median: 1.7 hours (0.9 to 2.8 hours) (Bradley 2016)

Adults: Mean: 3.27 hours

Avibactam:

Children ≥6 years to <12 years: Median: 1.7 hours (0.9 to 2 hours) (Bradley 2016)

Children ≥12 years and Adolescents: Median: 1.6 hours (0.9 to 2.8 hours) (Bradley 2016)

Adults: Mean: 2.22 hours

Multiple dose: Adults: Mean: Ceftazidime: 2.76 hours; Avibactam: 2.71 hours

Excretion: Ceftazidime: Urine (~80% to 90% as unchanged drug); Avibactam: Urine (97%)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Half-life increases in patients with impaired renal function; AUC of avibactam increases 2.6-fold, 3.8-fold, and 7-fold in patients with mild, moderate or severe renal impairment, respectively.

Anti-infective considerations:

Parameters associated with efficacy:

Ceftazidime (data on monotherapy for susceptible organisms): Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC):

Organism specific: Gram-negative bacteria (including P. aeruginosa): Goal: 35% to 40% fT > MIC (bacteriostatic in vitro); 60% to 70% fT > MIC (bactericidal in vitro); ~45% to 53% fT > MIC (microbiological response) (Craig 1995; MacVane 2014; Muller 2013).

Population specific: In critically ill patients in the ICU, minimum goal: ≥50% fT > MIC; preferred goal: ≥100% fT > MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% fT >4 times the MIC (Guilhaumou 2019).

Ceftazidime (in combination with avibactam): Interrelationship between ceftazidime exposure, avibactam exposure, MIC, and efficacy is not fully elucidated; at avibactam exposures that were associated with bacteriostatic and bactericidal activity, mean ceftazidime fT > MIC (ceftazidime MIC in the presence of a fixed avibactam concentration): ~50% (Berkhout 2015; Nichols 2018).

Avibactam (in combination with ceftazidime): Time dependent, associated with fT > threshold concentration (threshold concentration: 1 mg/L); goal: ≥ ~20% to 50% (Berkhout 2015; Coleman 2014; Crass 2019; Nichols 2018).

Postantibiotic effect: Generally little to no postantibiotic effect (Berkhout 2021; Pillar 2016).

Expected drug concentrations in patients with normal renal function:

Pediatric patients (hospitalized): Single dose (2-hour infusion): Cmax (peak): IV:

Infants and children 3 months to <2 years of age: Ceftazidime 50 mg/avibactam 12.5 mg per kg: Ceftazidime: 91.7 mg/L; Avibactam: 16.3 mg/L (Bradley 2016).

Children 2 to <12 years of age: Ceftazidime 50 mg/avibactam 12.5 mg per kg (maximum ceftazidime 2,000 mg/avibactam 500 mg): Ceftazidime: ~80 mg/L; Avibactam: ~14 mg/L (Bradley 2016).

Children and adolescents 12 to <18 years of age: Ceftazidime 2,000 mg/avibactam 500 mg: Ceftazidime: 79.8 mg/L; Avibactam: 15.1 mg/L (Bradley 2016).

Adults: Cmax (peak): IV:

Note: Adult doses are expressed as the combined amount of ceftazidime and avibactam.

Single dose, 30-minute infusion (healthy volunteers): 2.5 g: Ceftazidime: 93.17 mg/L; Avibactam: 23.33 mg/L (Merdjan 2015).

Steady state, 30-minute infusion (healthy volunteers): 2.5 g every 8 hours: Ceftazidime: 114.53 mg/L; Avibactam: 22.22 mg/L (Merdjan 2015).

Steady state, 2-hour infusion (patients with nosocomial pneumonia, including ventilator-associated): 2.5 g every 8 hours: Ceftazidime: 61.9 to 79 mg/L; Avibactam: 12 to 15.5 mg/L (Li 2019).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Zavicefta;
  • (AR) Argentina: Zavicefta;
  • (AT) Austria: Zavicefta;
  • (AU) Australia: Zavicefta;
  • (BE) Belgium: Zavicefta;
  • (BG) Bulgaria: Zavicefta;
  • (BR) Brazil: Torgena;
  • (CH) Switzerland: Zavicefta;
  • (CL) Chile: Zavicefta;
  • (CN) China: Zavicefta;
  • (CO) Colombia: Zavicefta;
  • (CZ) Czech Republic: Zavicefta;
  • (DE) Germany: Zavicefta;
  • (DO) Dominican Republic: Zavicefta;
  • (EE) Estonia: Zavicefta;
  • (EG) Egypt: Zavicefta;
  • (ES) Spain: Zavicefta;
  • (ET) Ethiopia: Zavicefta;
  • (FI) Finland: Zavicefta;
  • (FR) France: Zavicefta;
  • (GB) United Kingdom: Zavicefta;
  • (GR) Greece: Zavicefta;
  • (HK) Hong Kong: Zavicefta;
  • (HU) Hungary: Zavicefta;
  • (ID) Indonesia: Zavicefta;
  • (IE) Ireland: Zavicefta;
  • (IN) India: Avicrest | Cefactiv | Cipcza | Zavicefta;
  • (IT) Italy: Zavicefta;
  • (KW) Kuwait: Zavicefta;
  • (LB) Lebanon: Zavicefta;
  • (LT) Lithuania: Zavicefta;
  • (LV) Latvia: Zavicefta;
  • (MX) Mexico: Zavicefta;
  • (MY) Malaysia: Zavicefta;
  • (NL) Netherlands: Zavicefta;
  • (NO) Norway: Zavicefta;
  • (NZ) New Zealand: Avycaz;
  • (PH) Philippines: Zavicefta;
  • (PK) Pakistan: Zavicefta;
  • (PL) Poland: Zavicefta;
  • (PR) Puerto Rico: Avycaz;
  • (PT) Portugal: Zavicefta;
  • (QA) Qatar: Zavicefta;
  • (RO) Romania: Zavicefta;
  • (RU) Russian Federation: Zavicefta;
  • (SA) Saudi Arabia: Zavicefta;
  • (SE) Sweden: Zavicefta;
  • (SI) Slovenia: Zavicefta;
  • (SK) Slovakia: Zavicefta;
  • (TH) Thailand: Zavicefta;
  • (TN) Tunisia: Zavicefta;
  • (TR) Turkey: Zavicefta;
  • (TW) Taiwan: Zavicefta;
  • (UA) Ukraine: Zavicefta;
  • (ZA) South Africa: Zavicefta
  1. Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1 [PubMed 32383061]
  2. Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. J Antimicrob Chemother. 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359 [PubMed 32910809]
  3. American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610. doi:10.1542/peds.2011-1330 [PubMed 21873693]
  4. Autore G, Bernardi L, La Scola C, et al. Management of pediatric urinary tract infections: a Delphi study. Antibiotics (Basel). 2022;11(8):1122. doi:10.3390/antibiotics11081122 [PubMed 36009990]
  5. Avycaz (ceftazidime/avibactam) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2022.
  6. Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother. 2015;60(1):368-375. doi:10.1128/AAC.01269-15 [PubMed 26525790]
  7. Berkhout J, Melchers MJ, van Mil AC, Lagarde CM, Nichols WW, Mouton JW. Evaluation of the post-antibiotic effect in vivo for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections. J Chemother. Published online March 6, 2021. doi:10.1080/1120009X.2021.1892365 [PubMed 33682636]
  8. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  9. Bradley JS, Armstrong J, Arrieta A, et al. Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients. Antimicrob Agents Chemother. 2016;60(10):6252-6259. doi:10.1128/AAC.00862-16 [PubMed 27503642]
  10. Chalhoub H, Tunney M, Elborn JS, et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother. 2015. [PubMed 25587996]
  11. Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014;58(6):3366-3372. doi:10.1128/AAC.00080-14 [PubMed 24687507]
  12. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22(1-2):89-96. doi:10.1016/0732-8893(95)00053-d [PubMed 7587056]
  13. Crass RL, Pai MP. Pharmacokinetics and pharmacodynamics of β-lactamase inhibitors. Pharmacotherapy. 2019;39(2):182-195. doi:10.1002/phar.2210 [PubMed 30589457]
  14. Das S, Li J, Riccobene T, et al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019;63(4):e02187-18. doi:10.1128/AAC.02187-18 [PubMed 30670413]
  15. Diarra A, Pascal L, Carpentier B, et al Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia. Infect Dis Now. 2021;51(7):637-638. doi:10.1016/j.idnow.2021.01.014 [PubMed 33870895]
  16. Expert opinion. Senior Renal Editorial Team:Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc,FSHP, FISAC; Michael Heung, MD, MS.
  17. Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. JAMA Netw Open. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951 [PubMed 32364593]
  18. Gatti M, Pea F. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. Expert Rev Clin Pharmacol. 2021;14(5):583-599. doi:10.1080/17512433.2021.1901574 [PubMed 33687300]
  19. Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16. doi:10.1002/jhbp.518 [PubMed 29090866]
  20. Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019;23(1):104. doi:10.1186/s13054-019-2378-9 [PubMed 30925922]
  21. Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 20, 2021.
  22. Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475-485. [PubMed 25716293] 10.1016/S1473-3099(14)70950-8
  23. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353 [PubMed 27418577]
  24. Li J, Lovern M, Green ML, et al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups. Clin Transl Sci. 2019;12(2):151-163. doi:10.1111/cts.12585 [PubMed 30221827]
  25. Li J, Lovern M, Riccobene T, et al. Considerations in the selection of renal dosage adjustments for patients with serious infections and lessons learned from the development of ceftazidime-avibactam. Antimicrob Agents Chemother. 2020;64(4):e02105-19. doi:10.1128/AAC.02105-19 [PubMed 32015049]
  26. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68(5):1183-1192. doi:10.1093/jac/dks523 [PubMed 23391714]
  27. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1359-1364. doi:10.1128/AAC.01463-13 [PubMed 24342637]
  28. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x [PubMed 21793988]
  29. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380-1389. doi:10.1093/cid/ciw133 [PubMed 26962078]
  30. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. doi:10.1089/sur.2016.261 [PubMed 28085573]
  31. Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35(5):307-317. doi:10.1007/s40261-015-0283-9 [PubMed 25813217]
  32. Merdjan H, Tarral A, Das S, Li J. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211-218. doi:10.1002/jcph.793 [PubMed 27402250]
  33. Mojica MF, Ouellette CP, Leber A, et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother. 2016;60(9):5130-5134. doi:10.1128/AAC.00264-16 [PubMed 27551008]
  34. Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68(4):900-906. doi:10.1093/jac/dks468 [PubMed 23190766]
  35. Nichols WW, Newell P, Critchley IA, Riccobene T, Das S. Avibactam pharmacokinetic/pharmacodynamic targets. Antimicrob Agents Chemother. 2018;62(6):e02446-17. doi:10.1128/AAC.02446-17 [PubMed 29610208]
  36. Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Lett Appl Microbiol. 2016;63(2):96-102. doi:10.1111/lam.12592 [PubMed 27221329]
  37. Pistolesi V, Morabito S, Di Mario F, Regolisti G, Cantarelli C, Fiaccadori E. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy. Antimicrob Agents Chemother. 2019;63(8):e00583-19. doi:10.1128/AAC.00583-19 [PubMed 31109983]
  38. Refer to manufacturer's labeling.
  39. Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027 [PubMed 24429437]
  40. Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162 [PubMed 25992746]
  41. Stein GE, Smith CL, Scharmen A, et al. Pharmacokinetic and pharmacodynamic analysis of ceftazidime/avibactam in critically ill patients. Surg Infect (Larchmt). 2019;20(1):55-61. doi:10.1089/sur.2018.141 [PubMed 30351195]
  42. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections. Clin Infect Dis. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013 [PubMed 34864936]
  43. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022b;75(2):187-212. doi:10.1093/cid/ciac268 [PubMed 35439291]
  44. Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285-295. doi:10.1016/S1473-3099(17)30747-8 [PubMed 29254862]
  45. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  46. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754-762. doi:10.1093/cid/ciw378 [PubMed 27313268]
  47. Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2017;61(7):e00464-17. doi:10.1128/AAC.00464-17 [PubMed 28416553]
  48. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):e00115-e00120. doi:10.1128/CMR.00115-20 [PubMed 33177185]
  49. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159-177. [PubMed 23371303] 10.1007/s40265-013-0013-7
Topic 100152 Version 128.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟